Schechter Investment Advisors LLC Sells 5,633 Shares of CVS Health Co. (NYSE:CVS)

Schechter Investment Advisors LLC cut its holdings in shares of CVS Health Co. (NYSE:CVS - Free Report) by 50.1% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 5,609 shares of the pharmacy operator's stock after selling 5,633 shares during the period. Schechter Investment Advisors LLC's holdings in CVS Health were worth $252,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in CVS. United Advisor Group LLC purchased a new stake in CVS Health in the third quarter worth $206,000. M&G PLC grew its position in shares of CVS Health by 2.1% in the 3rd quarter. M&G PLC now owns 909,675 shares of the pharmacy operator's stock worth $57,310,000 after buying an additional 18,955 shares during the period. Poplar Forest Capital LLC increased its stake in shares of CVS Health by 27.1% in the 3rd quarter. Poplar Forest Capital LLC now owns 486,074 shares of the pharmacy operator's stock worth $30,564,000 after acquiring an additional 103,602 shares in the last quarter. WoodTrust Financial Corp purchased a new position in CVS Health during the 3rd quarter valued at about $231,000. Finally, Montecito Bank & Trust boosted its stake in CVS Health by 22.7% during the third quarter. Montecito Bank & Trust now owns 17,190 shares of the pharmacy operator's stock worth $1,081,000 after acquiring an additional 3,178 shares in the last quarter. Hedge funds and other institutional investors own 80.66% of the company's stock.

CVS Health Price Performance

Shares of CVS stock traded up $1.09 during mid-day trading on Friday, hitting $66.34. The company had a trading volume of 10,082,148 shares, compared to its average volume of 11,965,158. CVS Health Co. has a 52-week low of $43.56 and a 52-week high of $80.75. The stock's 50 day moving average price is $56.42 and its 200-day moving average price is $56.73. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.81 and a quick ratio of 0.60. The company has a market capitalization of $83.64 billion, a P/E ratio of 18.12, a P/E/G ratio of 0.98 and a beta of 0.54.

Remove Ads

CVS Health (NYSE:CVS - Get Free Report) last released its quarterly earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.89 by $0.30. CVS Health had a net margin of 1.24% and a return on equity of 9.11%. Equities research analysts forecast that CVS Health Co. will post 5.89 earnings per share for the current year.

CVS Health Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, February 3rd. Investors of record on Thursday, January 23rd were paid a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a yield of 4.01%. The ex-dividend date of this dividend was Thursday, January 23rd. CVS Health's payout ratio is 72.68%.

Insider Activity at CVS Health

In other CVS Health news, SVP James David Clark sold 7,513 shares of the business's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $66.35, for a total transaction of $498,487.55. Following the transaction, the senior vice president now owns 8,394 shares in the company, valued at $556,941.90. The trade was a 47.23 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Michael F. Mahoney acquired 30,000 shares of the business's stock in a transaction on Tuesday, February 18th. The shares were purchased at an average price of $66.70 per share, for a total transaction of $2,001,000.00. Following the transaction, the director now directly owns 39,356 shares of the company's stock, valued at approximately $2,625,045.20. The trade was a 320.65 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.24% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on CVS. Argus set a $77.00 target price on shares of CVS Health in a report on Tuesday, February 18th. Wolfe Research boosted their target price on CVS Health from 67.00 to 70.00 and gave the stock an "overweight" rating in a report on Tuesday, February 11th. UBS Group reduced their price target on CVS Health from $62.00 to $59.00 and set a "neutral" rating for the company in a report on Tuesday, February 11th. Leerink Partners upgraded shares of CVS Health from a "market perform" rating to an "outperform" rating and upped their price target for the stock from $55.00 to $75.00 in a research note on Thursday, February 13th. Finally, Edward Jones upgraded shares of CVS Health from a "hold" rating to a "buy" rating in a research note on Thursday, January 30th. Four research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, CVS Health has a consensus rating of "Moderate Buy" and a consensus target price of $69.83.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.